Danaher Acquires Masimo in $10 Billion Deal

Medical device maker Masimo to operate as stand-alone company within Danaher's Diagnostics segment.

Published on Feb. 18, 2026

Got story updates? Submit your updates here. ›

Danaher, a diversified conglomerate, has struck a deal to acquire medical device company Masimo for nearly $10 billion. Danaher is expected to pay $180 per share in cash for Masimo, a 40% premium over the stock's previous closing price.

Why it matters

The acquisition of Masimo, a leader in patient monitoring devices, will expand Danaher's presence in the lucrative medical technology market. It also signals Danaher's strategy to grow its diagnostics business through strategic acquisitions.

The details

Masimo, based in Irvine, California, specializes in developing innovative patient monitoring technologies. Under the deal, Masimo will operate as a stand-alone company within Danaher's Diagnostics segment.

  • The deal is expected to be announced on February 17, 2026.

The players

Danaher

A diversified conglomerate that operates in the life sciences, diagnostics, and environmental & applied solutions markets.

Masimo

A medical device company based in Irvine, California that specializes in patient monitoring technologies.

Got photos? Submit your photos here. ›

What’s next

The acquisition is subject to regulatory approval and is expected to close in the coming months.

The takeaway

The Danaher-Masimo deal highlights the ongoing consolidation in the medical technology industry as companies seek to expand their product portfolios and market share.